While RTX targeting CD20 has been approved to be effective for patients with AAV and anti-GBM disease, the anti-CD52 monoclonal antibody targeting T cells may also be a potential therapy for DPPs in the future (30–32). This evidence concerns the gene CD52 and glioblastoma.